Stevens Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Stevens Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-14,271	Closed	-$85K	–	1078
2017 Q4	$85K	Buy	+14,271	New	+$86.7K	﹤0.01%	776
2017 Q3	–	Sell	-54,771	Closed	-$372K	–	1150
2017 Q2	$372K	Buy	54,771 +1,231	+2%	+$9.09K	0.01%	635
2017 Q1	$505K	Buy	+53,540	New	+$534K	0.02%	576
2016 Q1	–	Sell	-10,602	Closed	-$65K	–	1193
2015 Q4	$65K	Buy	+10,602	New	+$69.5K	﹤0.01%	873
2015 Q2	–	Sell	-18,431	Closed	-$110K	–	1324
2015 Q1	$110K	Buy	+18,431	New	+$116K	﹤0.01%	918
2014 Q2	–	Sell	-21,262	Closed	-$87K	–	1393
2014 Q1	$87K	Buy	+21,262	New	+$109K	﹤0.01%	1013
2013 Q4	–	Sell	-19,785	Closed	-$99K	–	1319
2013 Q3	$99K	Buy	+19,785	New	+$107K	﹤0.01%	973

Other funds holding PGNX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Stevens Capital Management's PGNX Position: Q1 2018 in Review

Stevens Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2018, closing a stake of 14,271 shares — an estimated $85K sold.

Stevens Capital Management first reported a position in PGNX in Q3 2013 and held it in 7 quarters. The position peaked at $505K in Q1 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q1 2018.

Stevens Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
Stevens Capital Management sold 14,271 Progenics Pharmaceuticals Inc shares in Q1 2018, an estimated $85K.
Stevens Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 7 quarters.
Stevens Capital Management's Progenics Pharmaceuticals Inc position peaked at $505K in Q1 2017.
152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2018.

Based on Stevens Capital Management's 13F filing for Q1 2018, filed 8 May 2018.